论文部分内容阅读
目的分析自体外周血造血干细胞支持下高剂量化疗对于晚期乳腺癌化疗前后生活质量影响,为选择有效改善患者生活质量的干预措施提供依据。方法回顾性分析25例病例组行自体外周血造血干细胞支持下高剂量化疗的晚期乳腺癌患者临床资料,同期选取接受常规方案化疗的22例晚期乳腺癌患者为对照组。采用简明健康状况调查量表SF-36(MOS36-item short forum health survey)的缩减版本SF-12量表作为问卷调查表。在第1个时间点(T1)为治疗前,第2个时间点(T2)为第2周期高剂量化疗前和第4周期常规治疗前,第3个时间点(T3)为高剂量化疗结束3月随访时和常规剂量化疗结束后3月进行调查随访。采用t检验进行统计分析。结果高剂量化疗组和常规剂量组患者生活质量8个维度评分T2较T1均显著下降(P<0.05),T3较T1两组患者活力和社会功能维度仍显著下降(P<0.05),其他维度差异无统计学意义。T2时间点高剂量化疗组较常规剂量化疗组总体健康、生理功能、活力和社会功能维度显著下降(P<0.05),T1和T3时间点高剂量化疗组和常规剂量组差异无统计学意义。结论自体外周血造血干细胞支持下高剂量化疗导致乳腺癌患者总体健康、生理功能、活力和社会功能显著下降,但患者高剂量化疗缩短了治疗时间,使患者可更快的恢复正常生活。
Objective To analyze the influence of high-dose chemotherapy on the quality of life of advanced breast cancer patients before and after chemotherapy with the support of autologous peripheral blood hematopoietic stem cells, and to provide basis for selecting effective interventions to improve patients’ quality of life. Methods The clinical data of 25 patients with advanced breast cancer undergoing high-dose chemotherapy with autologous peripheral blood stem cells were retrospectively analyzed. Twenty-two patients with advanced breast cancer undergoing routine chemotherapy were selected as the control group. A scaled-down version of the SF-12 scale of the SF36 (MOS36-item short forum health survey) was used as a questionnaire. The first time point (T1) before treatment, the second time point (T2) for the second cycle of high-dose chemotherapy before and 4 cycles of conventional therapy before the third time point (T3) for high-dose chemotherapy March follow-up and conventional chemotherapy in March after the end of follow-up survey. Using t test for statistical analysis. Results The scores of quality of life in eight groups of high-dose chemotherapy group and conventional dose group were significantly lower than those of T1 (P <0.05), T3 and T1 group were still significantly lower than those of T1 group (P <0.05) The difference was not statistically significant. The total health, physiological function, vitality and social function dimension of high-dose chemotherapy group were significantly decreased at T2 time point (P <0.05). There was no significant difference between high-dose chemotherapy group and routine dose group at T1 and T3 time points. Conclusion High-dose chemotherapy with autologous peripheral blood stem cell-derived chemotherapy leads to a significant decrease in overall health, physiological function, vitality and social function in patients with breast cancer. However, high-dose chemotherapy shortens the treatment time and enables patients to resume their normal life more quickly.